Concepedia

Which concentration of the inhibitor should be used to predict in vivo drug interactions from in vitro data?

Kiyomi Ito, Kōji Chiba, Masato Horikawa, Michi Ishigami, Naomi Mizuno, Jun Aoki, Yasumasa Gotoh, Takafumi Iwatsubo, Shin-ichi Kanamitsu, Motohiro Kato,

AAPS PharmSci · 2002 · 86 citations · 44 references

DOIFull text

Open access

Concepts

References

44

Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole

Anu Varhe, Klaus T. Olkkola, Pertti J. Neuvonen · Clinical Pharmacology & Therapeutics · 1994 · 280 citations

, , +15

Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole.

Lisa L. von Moltke, David J. Greenblatt, Jerold S. Harmatz et al. · Journal of Pharmacology and Experimental Therapeutics · 1996 · 227 citations

, , +17

Warfarin-fluconazole. II. A metabolically based drug interaction: in vivo studies.

D J Black, Kent L. Kunze, Larry C. Wienkers et al. · Drug Metabolism and Disposition · 1996 · 178 citations

, , +17

Quantification and mechanism of the fluoxetine and tricyclic antidepressant interaction

Richard F. Bergstrom, Albert L. Peyton, Louis Lemberger · Clinical Pharmacology & Therapeutics · 1992 · 169 citations

, , +17

Pharmacokinetic interactions between two human immunodeficiency virus protease inhibitors, ritonavir and saquinavir*

Ann Hsu, G. Richard Granneman, Guoliang Cao et al. · Clinical Pharmacology & Therapeutics · 1998 · 164 citations

, , +17